title: Doxorubicin cardiomyopathy.
abstract: Established doxorubicin cardiomyopathy is a lethal disease. When congestive heart failure develops, mortality is approximately 50%. Extensive research has been done to understand the mechanism and pathophysiology of doxorubicin cardiomyopathy, and considerable knowledge and experience has been gained. Unfortunately, no effective treatment for established doxorubicin cardiomyopathy is presently available. Extensive research has been done and is being done to discover preventive treatments. However an effective and clinically applicable preventive treatment is yet to be discovered.
authors.affiliation: Department of Medicine, University of Iowa Carver College of Medicine, Iowa City, Iowa 52242-1081, USA. kanu-chatterjee @ uiowa.edu
authors.forename: Kanu
authors.initials: K
authors.lastname: Chatterjee
authors.forename: Jianqing
authors.initials: J
authors.lastname: Zhang
authors.forename: Norman
authors.initials: N
authors.lastname: Honbo
authors.forename: Joel S
authors.initials: JS
authors.lastname: Karliner
mesh_terms: D000903:Antibiotics, Antineoplastic / Q000009:adverse effects*; D009202:Cardiomyopathies / Q000139:chemically induced* / Q000175:diagnosis / Q000473:pathology / Q000628:therapy; D004317:Doxorubicin / Q000009:adverse effects*; D006801:Humans; D009206:Myocardium / Q000473:pathology
chemical_list: D000903:Antibiotics, Antineoplastic; D004317:Doxorubicin